Alzamend Competitors

ALZN Stock  USD 2.43  0.01  0.41%   
Alzamend Neuro competes with Synlogic, AC Immune, Context Therapeutics, Ensysce Biosciences, and DatChat; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Alzamend Neuro competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Alzamend Neuro to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Alzamend Neuro Correlation with its peers.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Alzamend Neuro competition on your existing holdings.
As of the 15th of August 2025, Return On Tangible Assets is likely to grow to -17.21. In addition to that, Return On Capital Employed is likely to drop to 4.19. At this time, Alzamend Neuro's Non Current Assets Total are very stable compared to the past year. As of the 15th of August 2025, Debt To Assets is likely to grow to 0.95, while Total Assets are likely to drop about 3.8 M.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.122.4012.31
Details
Intrinsic
Valuation
LowRealHigh
2.1946.8056.71
Details
2 Analysts
Consensus
LowTargetHigh
163.80180.00199.80
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-3.69-3.69-3.69
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Alzamend Neuro. Your research has to be compared to or analyzed against Alzamend Neuro's peers to derive any actionable benefits. When done correctly, Alzamend Neuro's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Alzamend Neuro.

Alzamend Neuro Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Alzamend Neuro and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Alzamend and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Alzamend Neuro does not affect the price movement of the other competitor.

High positive correlations

BFRISYBX
ACIUSYBX
BFRIACIU
CNTXSYBX
BFRICNTX
DATSVRPX
  

High negative correlations

BFRIVRPX
VRPXACIU
VRPXSYBX
BFRIDATS
VRPXCNTX
ENSCSYBX

Risk-Adjusted Indicators

There is a big difference between Alzamend Stock performing well and Alzamend Neuro Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alzamend Neuro's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Alzamend Neuro and related stocks such as Synlogic, Effector Therapeutics, and Galera Therapeutics Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Free Cash Flow YieldOperating Cash Flow Per Share
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareRoic
Inventory TurnoverNet Income Per Share
Payables TurnoverSales General And Administrative To Revenue
Research And Ddevelopement To RevenueCapex To Revenue
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioIncome Quality
RoePe Ratio
Return On Tangible AssetsEarnings Yield
Intangibles To Total AssetsCurrent Ratio
Receivables TurnoverDebt To Equity
Capex Per ShareRevenue Per Share
Debt To AssetsBook Value Per Share
Invested CapitalAverage Payables
Days Of Inventory On HandAverage Inventory
Cash Per ShareDays Payables Outstanding
Net Current Asset ValueTangible Asset Value
Ev To Operating Cash FlowEv To Free Cash Flow
Net Debt To E B I T D ATangible Book Value Per Share
Shareholders Equity Per ShareGraham Net Net
Average ReceivablesInterest Debt Per Share
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioPrice Book Value Ratio
Price Earnings To Growth RatioDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Days Of Payables OutstandingCash Conversion Cycle
Days Of Inventory OutstandingEnterprise Value Multiple
2010201120122013201420152016201720182019202020212022202320242025
SYBX(2.9 M)(2.9 M)(3.7 M)(6.4 M)(15.8 M)(25 M)(26.3 M)(40.4 M)(48.4 M)(48.7 M)(56.5 M)(58.1 M)(64.9 M)(57.3 M)(23.4 M)(24.5 M)
ACIU(11.2 M)(11.2 M)(11.2 M)(11.2 M)10.7 M20.3 M(7.1 M)(26.4 M)(51 M)45.4 M(62.1 M)(73 M)(70.8 M)(54.2 M)(50.9 M)(48.4 M)
CNTX(37.7 M)(37.7 M)(37.7 M)(37.7 M)(37.7 M)(37.7 M)(37.7 M)(24.6 M)(7.5 M)(7.5 M)6.6 M(10.5 M)(14.8 M)(24 M)(26.7 M)(28.1 M)
ENSC(31.2 K)(31.2 K)(31.2 K)(31.2 K)(31.2 K)(31.2 K)(31.2 K)(31.2 K)2.1 M1.5 M56.8 K(29.1 M)(25 M)(10.6 M)(8 M)(8.4 M)
DATS(29 K)(29 K)(29 K)(29 K)(29 K)(261 K)(1.5 M)(2.5 M)(4.9 M)(6.7 M)(1 M)(10.8 M)(12.1 M)(8.4 M)(4.2 M)(4.5 M)
BFRI(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(37.7 M)(640 K)(20.1 M)(17.8 M)(18.6 M)

Alzamend Neuro and related stocks such as Synlogic, Effector Therapeutics, and Galera Therapeutics Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Alzamend Neuro financial statement analysis. It represents the amount of money remaining after all of Alzamend Neuro operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Alzamend Neuro Competitive Analysis

The better you understand Alzamend Neuro competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Alzamend Neuro's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Alzamend Neuro's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALZN SYBX ACIU CNTX ENSC VRPX DATS BFRI
 0.41 
 2.43 
Alzamend
 3.33 
 1.45 
Synlogic
 3.18 
 2.13 
ACIU
 5.71 
 0.74 
Context
 4.19 
 2.06 
Ensysce
 19.05 
 0.25 
Virpax
 0.90 
 2.25 
DatChat
 2.11 
 0.97 
Biofrontera
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Current Valuation
Price To Book
Operating Margin
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Short Ratio
Target Price
Debt To Equity
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Alzamend Neuro Competition Performance Charts

Five steps to successful analysis of Alzamend Neuro Competition

Alzamend Neuro's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Alzamend Neuro in relation to its competition. Alzamend Neuro's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Alzamend Neuro in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Alzamend Neuro's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Alzamend Neuro, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Alzamend Neuro position

In addition to having Alzamend Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Chemicals Makers Thematic Idea Now

Chemicals Makers
Chemicals Makers Theme
Companies developing chemicals for crops, soil as well as human, and animals. The Chemicals Makers theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Makers Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
Check out Alzamend Neuro Correlation with its peers.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(101.88)
Return On Assets
(1.07)
Return On Equity
(6.57)
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.